Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.
Eugene ShenderovPedro Isaacsson VelhoAnas H AwanHao WangNooshin MirkheshtiTamara L LotanMichael A CarducciDrew M PardollMario A EisenbergerEmmanuel S AntonarakisPublished in: The Prostate (2019)
This exploratory study represents one of the largest cohorts of lung-only mHSPC patients to-date. The prevalence of actionable DNA-repair gene alterations was higher than anticipated (any DNA-repair mutation: 8 of 16, 50%). Compared to historical data, these patients appear to have exceptional and durable responses to first-line ADT. This study suggests that pulmonary-tropic mHSPC biology may be fundamentally different from nonpulmonary mHSPC.
Keyphrases
- dna repair
- prostate cancer
- end stage renal disease
- dna damage
- ejection fraction
- newly diagnosed
- chronic kidney disease
- squamous cell carcinoma
- peritoneal dialysis
- small cell lung cancer
- prognostic factors
- copy number
- patient reported outcomes
- oxidative stress
- electronic health record
- artificial intelligence
- data analysis
- single molecule